Moderna (MRNA) Sees $109.7 Million in Net ETF Buying on Nov. 12
The Single Most Important Metric For Moderna Stock
Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”
Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?
Why Moderna Stock Dropped on Thursday
Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
Moderna Outlines Next Phase of Growth at Analyst Day
Moderna Raises FY26 Sales Growth Guidance To 15%-25% From 10%; On Track To Achieve FY26 Gross Margin Expansion Of ~10 Percentage Points Excluding Litigation Settlement Charge; Expects Annual Cash Costs Of ~$4B-$4.5B Over 2027-2030; Sees Ending 2026 With ~$9B In Total Liquidity, Including Cash, Investments And Undrawn Borrowing Capacity
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
Moderna Stock Jumped 10% in 5 Sessions: Take Profits, or Buy More?
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Moderna Highlights JAMA Publication Of Real-World Comparative Effectiveness Data For COVID-19 Vaccine Adults Aged 65 Years and Older
Moderna to Present at Upcoming Conference in November 2026
Why is Moderna (MRNA) stock soaring today
Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Is Moderna (MRNA) Priced For Too Much Sales Growth?
Moderna (MRNA) Stock Fair Value Rises After Intismeran Data And Q3 Beat
MRNA support and resistance levels to watch
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.